Recent studies have identified TMB, MSI, DNMT, and MMRs as immunotherapy and tumor immune microenvironment-related factors, and may predicate the outcome of immunotherapy (Mandal et al., 2019; Samstein et al., 2019; Segovia et al., 2019). The gene discussed is DNMT1; the disease is neoplasm.